Vaerloese, Denmark

Marie Thryøse Kruse

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Novozymes A/s. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marie Thryøse Kruse. Retrieved from https://idiyas.com/inventor/marie-thryøse-kruse

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marie Thryøse Kruse and Her Patent Work

Introduction

Marie Thryøse Kruse is an inventor associated with Vaerloese, Denmark, and Novozymes A/S. Her recorded patent work concerns alpha-amylase variants and the polynucleotides that encode them.

Latest Patents

The available information lists one patent for Kruse: “ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME.” The patent title indicates work involving enzyme variants and the genetic sequences that encode them. 1 patent

Career Highlights

Kruse is associated with Novozymes A/S, a company known for biotechnology and enzyme-related innovation. Her listed patent reflects a contribution to research on alpha-amylase, an enzyme used in various industrial and scientific applications.

Collaborations

Kruse’s listed coworker is Dorota Nissen, who is identified as a woman. The information provided does not specify further details about their collaboration or respective roles in the patent.

Conclusion

Marie Thryøse Kruse’s recorded invention connects her work at Novozymes A/S with research into alpha-amylase variants and their encoding polynucleotides.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…